1ISG-016 Evaluation of substitution and switch to etanercept biosimilar and related cost savings

BACKGROUND: Etanercept is a biological drug that treats autoimmune diseases by inhibiting tumour necrosis factor (TNF) with a considerable economic impact on the hospital’s annual budget. Biosimilar therapies are expected to be less costly for healthcare systems. PURPOSE: The primary endpoint was to...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Eur J Hosp Pharm
Huvudupphovsmän: Moya-Carmona, I, Estaun-Martinez, C, Pedrosa-Ruiz, M, Dani-Ben, L, Fernández-Ovies, JM
Materialtyp: Artigo
Språk:Inglês
Publicerad: BMJ Group 2018
Ämnen:
Section 1: Introductory statements and governance
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535226/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.16
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk